407 related articles for article (PubMed ID: 32357912)
1. The application and prospect of CDK4/6 inhibitors in malignant solid tumors.
Du Q; Guo X; Wang M; Li Y; Sun X; Li Q
J Hematol Oncol; 2020 May; 13(1):41. PubMed ID: 32357912
[TBL] [Abstract][Full Text] [Related]
2. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
3. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
4. CDK4, CDK6/cyclin-D1 Complex Inhibition and Radiotherapy for Cancer Control: A Role for Autophagy.
Nardone V; Barbarino M; Angrisani A; Correale P; Pastina P; Cappabianca S; Reginelli A; Mutti L; Miracco C; Giannicola R; Giordano A; Pirtoli L
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445095
[TBL] [Abstract][Full Text] [Related]
5. Targeting CDK4 and CDK6: From Discovery to Therapy.
Sherr CJ; Beach D; Shapiro GI
Cancer Discov; 2016 Apr; 6(4):353-67. PubMed ID: 26658964
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
8. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens.
Kato S; Okamura R; Adashek JJ; Khalid N; Lee S; Nguyen V; Sicklick JK; Kurzrock R
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427211
[TBL] [Abstract][Full Text] [Related]
9. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.
Knudsen ES; Witkiewicz AK
Trends Cancer; 2017 Jan; 3(1):39-55. PubMed ID: 28303264
[TBL] [Abstract][Full Text] [Related]
10. CDK4 and CDK6 kinases: From basic science to cancer therapy.
Fassl A; Geng Y; Sicinski P
Science; 2022 Jan; 375(6577):eabc1495. PubMed ID: 35025636
[TBL] [Abstract][Full Text] [Related]
11. Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models.
Long F; He Y; Fu H; Li Y; Bao X; Wang Q; Wang Y; Xie C; Lou L
Cancer Sci; 2019 Apr; 110(4):1420-1430. PubMed ID: 30724426
[TBL] [Abstract][Full Text] [Related]
12. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D; Bardia A; Sellers WR
Clin Cancer Res; 2017 Jul; 23(13):3251-3262. PubMed ID: 28351928
[TBL] [Abstract][Full Text] [Related]
13. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D-CDK4/6 functions in cancer.
Gao X; Leone GW; Wang H
Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
[TBL] [Abstract][Full Text] [Related]
15. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
16. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
Chen F; Liu C; Zhang J; Xu W; Zhang Y
Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
18. Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents.
Tadesse S; Bantie L; Tomusange K; Yu M; Islam S; Bykovska N; Noll B; Zhu G; Li P; Lam F; Kumarasiri M; Milne R; Wang S
Br J Pharmacol; 2018 Jun; 175(12):2399-2413. PubMed ID: 28800675
[TBL] [Abstract][Full Text] [Related]
19. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications.
Yousuf M; Alam M; Shamsi A; Khan P; Hasan GM; Rizwanul Haque QM; Hassan MI
Int J Biol Macromol; 2022 Oct; 218():394-408. PubMed ID: 35878668
[TBL] [Abstract][Full Text] [Related]
20. A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
Guenther LM; Dharia NV; Ross L; Conway A; Robichaud AL; Catlett JL; Wechsler CS; Frank ES; Goodale A; Church AJ; Tseng YY; Guha R; McKnight CG; Janeway KA; Boehm JS; Mora J; Davis MI; Alexe G; Piccioni F; Stegmaier K
Clin Cancer Res; 2019 Feb; 25(4):1343-1357. PubMed ID: 30397176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
